BASKING RIDGE, N.J., Feb. 12 Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 2009 Wharton Healthcare Business Conference in Philadelphia, PA on Friday, February 20, 2009, at 1:35 Eastern Time. Dr. Mazzo's presentation will include a review of the Company's lead development product, REG1, its pipeline and enterprise-level business initiatives.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched active control agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.
Regado's lead program, REG1, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007), which can be used to completely or selectively lower the anticoagulant effect. Regado recently completed a phase 2a study of REG1 in percutaneous coronary intervention (PCI) and is planning the initiation of a rigorous phase 2b program in that same indication in 3Q2009.
SOURCE Regado Biosciences, Inc.